SERB and BTG Specialty Pharmaceuticals have appointed Ben Watt as the group’s new Chief Financial Officer (CFO).
Watt is an experienced CFO with a track record of building global finance teams and integrating business acquisitions.
Watt most recently served as CFO of Crouzet, an independent manufacturer of electronic components used in heavily regulated industries. He previously worked as a Director at Eight Advisory, a Paris-based advisory firm focused on due diligence for leveraged buyout funds and large corporations, with extensive exposure to the US and international markets. He started his career in audit and due diligence at Arthur Andersen.
Anthony Higham, who was appointed CEO of the group in September 2021, says: “Ben is a highly skilled practitioner, adept at complex business integrations, building high-performing teams, and working with private equity backers. We are confident that he will deliver the broad strategic perspective and rigorous attention to detail needed to accomplish our goals.”
Ben graduated with a First-Class degree in Law from the University of Edinburgh. He spent an exchange year at Université de Poitiers in France and is fluent in French. He received a CA (CPA equivalent) from the Institute of Chartered Accountants of Scotland.
SERB acquired BTG Specialty Pharmaceuticals in March 2021. SERB is a pan-European specialty pharmaceutical group providing a reliable supply of prescription medicines to patient suffering from rare and life-threatening diseases. BTG develops, manufactures, and commercialises antidotes that counteract the potentially life-threatening effects associated with exposure to certain toxins. Together, SERB and BTG are a fully integrated, global specialty pharmaceutical platform and a dedicated ally to healthcare providers treating patients with critical conditions.
Backed by Charterhouse Capital Partners LLP, Partners Group, and Merieux Equity Partners, the firm has more than 400 employees in 11 offices, advanced manufacturing facilities, and a direct commercial presence in all major pharmaceutical markets worldwide.
